CHAPEL HILL, N.C. - Nov. 8, 2013 - The competitive intelligence (CI) function within pharmaceutical and related industries plays an incremental role in transforming competitive data into actionable insights that have a financial impact for the company. Despite this, the CI function is still not seen as a traditional corporate function, such as Finance or Sales. Because of this, the value of the function remains poorly understood by senior leadership.
Recent research by benchmarking firm Best Practices, LLC offers critical insights for healthcare leaders on how to increase the value of their CI function. Value of the CI function is often judged by a leader's ability to 'move the needle' by producing some kind of measurable financial outcome for their company. In order to justify the function to leaders, savvy groups must measure their CI impact in financial terms that executives can understand and believe.
The report, "How Successful Companies Create and Develop a High-Value CI Function to Drive Better Business Decisions," identifies best practices and innovative methods for improving the strategic role and impact of the CI function within the pharmaceutical and related industries. The study also identifies current trends in structuring and activities completed by the function that will allow leaders to evaluate their organization's CI function relative to other leading companies.
Key study topics covered include:
To access the full report or to download a complimentary summary containing insights found in this report, click here.
For more information on other recent primary research studies, contact us at 919.403.0251 or visit our website at http://www.best-in-class.com.